A randomized, blinded, controlled, multi-centered field study assessing the treatment of gastrointestinal nematode infections in cats with fluralaner plus moxidectin spot-on solution (Bravecto® Plus)

Nadja Rohdich, Eva Zschiesche, Oliver Wolf, Wolfgang Loehlein, Zvezdelina Kirkova, Petar Iliev, Dhimitër Rapti, Rezart Postoli, Balázs Capári, R. Farkas, Rainer K.A. Roepke

Research output: Contribution to journalArticle

Abstract

BACKGROUND: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) was developed for the treatment of nematode infections as well as providing 12 weeks of protection against insect and acarine parasites in cats. The effectiveness and safety of this product against feline gastrointestinal nematodes was assessed in naturally-infested, client-owned cats under field conditions in Albania, Bulgaria, Germany and Hungary. METHODS: To be eligible for enrollment in this investigator-blinded study cats had to be at least 10 weeks-old, weigh at least 1.2 kg, be clinically healthy, and have a faecal sample testing positive for nematodes no more than eight days prior to treatment. Cats were stratified into blocks of three in order of presentation at each center and randomly allocated in a 2:1 ratio to be treated topically on Day 0 with fluralaner plus moxidectin (minimum dose rates 40 mg/kg and 2 mg/kg, respectively) or emodepside plus praziquantel (minimum dose rates 3 mg/kg and 12 mg/kg, respectively) (Profender®). Faecal samples were collected from cats prior to treatment and 14 ± 4 days later. RESULTS: There were 182 cats randomized to the fluralaner plus moxidectin group, and 91 to the emodepside plus praziquantel group. Prior to treatment the most commonly identified nematode egg was Toxocara cati, found in 79.1 and 82.4% of cats in the fluralaner plus moxidectin and emodepside plus praziquantel groups, respectively. Eggs of Toxascaris leonina were found in 8.2 and 6.6% of cats; of hookworms in 30.8 and 24.2%; and of Capillaria spp. in 7.1 and 4.3%, respectively. After treatment, faecal samples from 98.3% of fluralaner plus moxidectin treated and 96.6% of emodepside plus praziquantel-treated cats were free of nematode ova. Geometric mean faecal egg count reductions for T. cati, the only eggs found in post-treatment faecal samples, were 99.97% and 99.93%, respectively. Treatment with fluralaner plus moxidectin was non-inferior to emodepside plus praziquantel. Both products were safe and well tolerated by cats treated under field conditions. CONCLUSIONS: This field study confirms that, in addition to 12-week extended duration flea and tick control, fluralaner plus moxidectin provides broad spectrum treatment of nematodes in cats.

Original languageEnglish
Number of pages1
JournalParasites & vectors
Volume11
Issue number1
DOIs
Publication statusPublished - Nov 19 2018

Fingerprint

Nematode Infections
Cats
Praziquantel
Ovum
Eggs
Toxascaris
A1443 compound
milbemycin
Albania
Capillaria
Tick Control
Toxocara
Ancylostomatoidea
Siphonaptera
Bulgaria
Hungary
Felidae
Germany
Insects
Parasites

Keywords

  • Bravecto Plus
  • Cat
  • Emodepside
  • Field study
  • Fluralaner
  • Hookworms
  • Lungworms
  • Moxidectin
  • Praziquantel
  • Roundworms

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

A randomized, blinded, controlled, multi-centered field study assessing the treatment of gastrointestinal nematode infections in cats with fluralaner plus moxidectin spot-on solution (Bravecto® Plus). / Rohdich, Nadja; Zschiesche, Eva; Wolf, Oliver; Loehlein, Wolfgang; Kirkova, Zvezdelina; Iliev, Petar; Rapti, Dhimitër; Postoli, Rezart; Capári, Balázs; Farkas, R.; Roepke, Rainer K.A.

In: Parasites & vectors, Vol. 11, No. 1, 19.11.2018.

Research output: Contribution to journalArticle

Rohdich, Nadja ; Zschiesche, Eva ; Wolf, Oliver ; Loehlein, Wolfgang ; Kirkova, Zvezdelina ; Iliev, Petar ; Rapti, Dhimitër ; Postoli, Rezart ; Capári, Balázs ; Farkas, R. ; Roepke, Rainer K.A. / A randomized, blinded, controlled, multi-centered field study assessing the treatment of gastrointestinal nematode infections in cats with fluralaner plus moxidectin spot-on solution (Bravecto® Plus). In: Parasites & vectors. 2018 ; Vol. 11, No. 1.
@article{80b99a5ad9a2410394ac1e9c74174ef2,
title = "A randomized, blinded, controlled, multi-centered field study assessing the treatment of gastrointestinal nematode infections in cats with fluralaner plus moxidectin spot-on solution (Bravecto{\circledR} Plus)",
abstract = "BACKGROUND: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto{\circledR} Plus) was developed for the treatment of nematode infections as well as providing 12 weeks of protection against insect and acarine parasites in cats. The effectiveness and safety of this product against feline gastrointestinal nematodes was assessed in naturally-infested, client-owned cats under field conditions in Albania, Bulgaria, Germany and Hungary. METHODS: To be eligible for enrollment in this investigator-blinded study cats had to be at least 10 weeks-old, weigh at least 1.2 kg, be clinically healthy, and have a faecal sample testing positive for nematodes no more than eight days prior to treatment. Cats were stratified into blocks of three in order of presentation at each center and randomly allocated in a 2:1 ratio to be treated topically on Day 0 with fluralaner plus moxidectin (minimum dose rates 40 mg/kg and 2 mg/kg, respectively) or emodepside plus praziquantel (minimum dose rates 3 mg/kg and 12 mg/kg, respectively) (Profender{\circledR}). Faecal samples were collected from cats prior to treatment and 14 ± 4 days later. RESULTS: There were 182 cats randomized to the fluralaner plus moxidectin group, and 91 to the emodepside plus praziquantel group. Prior to treatment the most commonly identified nematode egg was Toxocara cati, found in 79.1 and 82.4{\%} of cats in the fluralaner plus moxidectin and emodepside plus praziquantel groups, respectively. Eggs of Toxascaris leonina were found in 8.2 and 6.6{\%} of cats; of hookworms in 30.8 and 24.2{\%}; and of Capillaria spp. in 7.1 and 4.3{\%}, respectively. After treatment, faecal samples from 98.3{\%} of fluralaner plus moxidectin treated and 96.6{\%} of emodepside plus praziquantel-treated cats were free of nematode ova. Geometric mean faecal egg count reductions for T. cati, the only eggs found in post-treatment faecal samples, were 99.97{\%} and 99.93{\%}, respectively. Treatment with fluralaner plus moxidectin was non-inferior to emodepside plus praziquantel. Both products were safe and well tolerated by cats treated under field conditions. CONCLUSIONS: This field study confirms that, in addition to 12-week extended duration flea and tick control, fluralaner plus moxidectin provides broad spectrum treatment of nematodes in cats.",
keywords = "Bravecto Plus, Cat, Emodepside, Field study, Fluralaner, Hookworms, Lungworms, Moxidectin, Praziquantel, Roundworms",
author = "Nadja Rohdich and Eva Zschiesche and Oliver Wolf and Wolfgang Loehlein and Zvezdelina Kirkova and Petar Iliev and Dhimit{\"e}r Rapti and Rezart Postoli and Bal{\'a}zs Cap{\'a}ri and R. Farkas and Roepke, {Rainer K.A.}",
year = "2018",
month = "11",
day = "19",
doi = "10.1186/s13071-018-3169-x",
language = "English",
volume = "11",
journal = "Parasites and Vectors",
issn = "1756-3305",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A randomized, blinded, controlled, multi-centered field study assessing the treatment of gastrointestinal nematode infections in cats with fluralaner plus moxidectin spot-on solution (Bravecto® Plus)

AU - Rohdich, Nadja

AU - Zschiesche, Eva

AU - Wolf, Oliver

AU - Loehlein, Wolfgang

AU - Kirkova, Zvezdelina

AU - Iliev, Petar

AU - Rapti, Dhimitër

AU - Postoli, Rezart

AU - Capári, Balázs

AU - Farkas, R.

AU - Roepke, Rainer K.A.

PY - 2018/11/19

Y1 - 2018/11/19

N2 - BACKGROUND: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) was developed for the treatment of nematode infections as well as providing 12 weeks of protection against insect and acarine parasites in cats. The effectiveness and safety of this product against feline gastrointestinal nematodes was assessed in naturally-infested, client-owned cats under field conditions in Albania, Bulgaria, Germany and Hungary. METHODS: To be eligible for enrollment in this investigator-blinded study cats had to be at least 10 weeks-old, weigh at least 1.2 kg, be clinically healthy, and have a faecal sample testing positive for nematodes no more than eight days prior to treatment. Cats were stratified into blocks of three in order of presentation at each center and randomly allocated in a 2:1 ratio to be treated topically on Day 0 with fluralaner plus moxidectin (minimum dose rates 40 mg/kg and 2 mg/kg, respectively) or emodepside plus praziquantel (minimum dose rates 3 mg/kg and 12 mg/kg, respectively) (Profender®). Faecal samples were collected from cats prior to treatment and 14 ± 4 days later. RESULTS: There were 182 cats randomized to the fluralaner plus moxidectin group, and 91 to the emodepside plus praziquantel group. Prior to treatment the most commonly identified nematode egg was Toxocara cati, found in 79.1 and 82.4% of cats in the fluralaner plus moxidectin and emodepside plus praziquantel groups, respectively. Eggs of Toxascaris leonina were found in 8.2 and 6.6% of cats; of hookworms in 30.8 and 24.2%; and of Capillaria spp. in 7.1 and 4.3%, respectively. After treatment, faecal samples from 98.3% of fluralaner plus moxidectin treated and 96.6% of emodepside plus praziquantel-treated cats were free of nematode ova. Geometric mean faecal egg count reductions for T. cati, the only eggs found in post-treatment faecal samples, were 99.97% and 99.93%, respectively. Treatment with fluralaner plus moxidectin was non-inferior to emodepside plus praziquantel. Both products were safe and well tolerated by cats treated under field conditions. CONCLUSIONS: This field study confirms that, in addition to 12-week extended duration flea and tick control, fluralaner plus moxidectin provides broad spectrum treatment of nematodes in cats.

AB - BACKGROUND: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) was developed for the treatment of nematode infections as well as providing 12 weeks of protection against insect and acarine parasites in cats. The effectiveness and safety of this product against feline gastrointestinal nematodes was assessed in naturally-infested, client-owned cats under field conditions in Albania, Bulgaria, Germany and Hungary. METHODS: To be eligible for enrollment in this investigator-blinded study cats had to be at least 10 weeks-old, weigh at least 1.2 kg, be clinically healthy, and have a faecal sample testing positive for nematodes no more than eight days prior to treatment. Cats were stratified into blocks of three in order of presentation at each center and randomly allocated in a 2:1 ratio to be treated topically on Day 0 with fluralaner plus moxidectin (minimum dose rates 40 mg/kg and 2 mg/kg, respectively) or emodepside plus praziquantel (minimum dose rates 3 mg/kg and 12 mg/kg, respectively) (Profender®). Faecal samples were collected from cats prior to treatment and 14 ± 4 days later. RESULTS: There were 182 cats randomized to the fluralaner plus moxidectin group, and 91 to the emodepside plus praziquantel group. Prior to treatment the most commonly identified nematode egg was Toxocara cati, found in 79.1 and 82.4% of cats in the fluralaner plus moxidectin and emodepside plus praziquantel groups, respectively. Eggs of Toxascaris leonina were found in 8.2 and 6.6% of cats; of hookworms in 30.8 and 24.2%; and of Capillaria spp. in 7.1 and 4.3%, respectively. After treatment, faecal samples from 98.3% of fluralaner plus moxidectin treated and 96.6% of emodepside plus praziquantel-treated cats were free of nematode ova. Geometric mean faecal egg count reductions for T. cati, the only eggs found in post-treatment faecal samples, were 99.97% and 99.93%, respectively. Treatment with fluralaner plus moxidectin was non-inferior to emodepside plus praziquantel. Both products were safe and well tolerated by cats treated under field conditions. CONCLUSIONS: This field study confirms that, in addition to 12-week extended duration flea and tick control, fluralaner plus moxidectin provides broad spectrum treatment of nematodes in cats.

KW - Bravecto Plus

KW - Cat

KW - Emodepside

KW - Field study

KW - Fluralaner

KW - Hookworms

KW - Lungworms

KW - Moxidectin

KW - Praziquantel

KW - Roundworms

UR - http://www.scopus.com/inward/record.url?scp=85056601908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056601908&partnerID=8YFLogxK

U2 - 10.1186/s13071-018-3169-x

DO - 10.1186/s13071-018-3169-x

M3 - Article

C2 - 30449275

AN - SCOPUS:85056601908

VL - 11

JO - Parasites and Vectors

JF - Parasites and Vectors

SN - 1756-3305

IS - 1

ER -